Type III Interferons, IL-28 and IL-29, Are Increased in Chronic HCV Infection and Induce Myeloid Dendritic Cell-Mediated FoxP3+ Regulatory T Cells
Authors:
Open Access
- 10 October 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10) , e44915
Abstract
Hepatitis C virus (HCV) is difficult to eradicate and type III interferons (IFN-λ, composed of IL-28A, IL-28B and IL-29) are novel therapeutic candidates. We hypothesized that IFN-λ have immunomodulatory effects in HCV- infected individuals. We analyzed the expression of IFN-λ and its receptor (composed of IL-10R2 and IFN-λR subunits) in the blood and livers of patients with chronic (c)HCV infection compared to controls (those who cleared HCV by sustained virological response, SVR, and those with liver inflammation of non-viral origin, non-alcoholic steatohepatitis, NASH). We also compared the proliferative capacity of dendritic cells (DCs) obtained from healthy individuals and those with chronic HCV using a mixed leukocyte reaction combined with 3H-Td incorporation. In addition, the composition of the IFN-λ receptor (IFN-λR) on myeloid DCs, plasmacytoid DCs, PBMCs, and T cells was determined by FACS analysis. We report that the expression of IFN-λ protein in serum and mRNA in liver is increased in cHCV patients, but not in those with HCV SVR or NASH, compared to controls. Liver level of IFN-λR mirrored the expression of serum IFN-λ and was higher in cHCV, compared to controls and HCV-SVR patients, suggesting that elevation of IFN-λ and IFN-λR are HCV-dependent. We further identified that innate immune cell populations expressed complete IFN-λ receptor. In vitro, recombinant IFN-λ promoted differentiation of monocyte-derived dendritic cells (DCs) into a phenotype with low T cell stimulatory capacity and high PD-L1 expression, which further promoted expansion of existing regulatory T cells. IFN-λ-DCs failed to induce de novo generation of regulatory T cells. The inhibitory capacity of IFN-λ-DCs was counteracted by recombinant IL-12 and by neutralization of the PD-1/PD-L1 system. Our novel findings of the immunomodulatory effect of IFN-λ contribute to the understanding of the anti-inflammatory and/or anti-viral potential of IFN-λ in cHCV.Keywords
This publication has 25 references indexed in Scilit:
- Impact of IL28B gene polymorphisms on interferon- 3 plasma levels during pegylated interferon- /ribavirin therapy for chronic hepatitis C in patients coinfected with HIVJournal of Antimicrobial Chemotherapy, 2012
- Type III Interferon (IFN) Induces a Type I IFN-Like Response in a Restricted Subset of Cells through Signaling Pathways Involving both the Jak-STAT Pathway and the Mitogen-Activated Protein KinasesJournal of Virology, 2007
- IL-28 and IL-29: Newcomers to the interferon familyBiochimie, 2007
- Interferons α and λ Inhibit Hepatitis C Virus Replication With Distinct Signal Transduction and Gene Regulation KineticsGastroenterology, 2006
- Impaired ability of interferon‐alpha‐primed dendritic cells to stimulate Th1‐type CD4 T‐cell response in chronic hepatitis C virus infectionJournal of Viral Hepatitis, 2006
- Interleukin‐29 uses a type 1 interferon‐like program to promote antiviral responses in human hepatocytes†Hepatology, 2006
- Elevated CD4+/CD25+ T cell frequency and function during acute hepatitis C presage chronic evolutionGut, 2006
- Lambda Interferon (IFN-λ), a Type III IFN, Is Induced by Viruses and IFNs and Displays Potent Antiviral Activity against Select Virus Infections In VivoJournal of Virology, 2006
- Increased hepatitis C virus (HCV)-specific CD4+CD25 + regulatory T lymphocytes and reduced HCV-specific CD4+ T cell response in HCV-infected patients with normalversusabnormal alanine aminotransferase levelsClinical and Experimental Immunology, 2006
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002